| Autor: |
Jha A; Emergent BioSolutions Canada Inc., Winnipeg, MB R3T 5Y3, Canada., Doyle-Eisele M; Lovelace Biomedical Research Institute, Albuquerque, NM 87108, USA., Revelli D; Lovelace Biomedical Research Institute, Albuquerque, NM 87108, USA., Carnelley T; Emergent BioSolutions Canada Inc., Winnipeg, MB R3T 5Y3, Canada., Barker D; Emergent BioSolutions Canada Inc., Winnipeg, MB R3T 5Y3, Canada., Kodihalli S; Emergent BioSolutions Canada Inc., Winnipeg, MB R3T 5Y3, Canada. |
| Abstrakt: |
Despite ongoing vaccination efforts to prevent SARS-CoV-2 infections, treatment tools are still necessary to address the ongoing COVID-19 pandemic. We report here that COVID-HIGIV, a human immunoglobulin product for treatment of COVID-19, provided a significant survival benefit in SARS-CoV-2 infected transgenic mice compared to controls. COVID-HIGIV also has similar pharmacokinetic profiles in healthy and SARS-CoV-2 infected mice over time after intravenous administration, with identical or comparable Tmax, Cmax, AUC 0-∞ and Cl. AUC 0-last increased and mean residence time, T 1/2 , and Vd reduced in infected animals compared to healthy animals. These data suggest that COVID-HIGIV may be an effective treatment for SARS-CoV-2 infection when given early after exposure. |
